Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03056001
Title Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Edward Kim
Indications

sarcoma

Therapies

Doxorubicin + Pembrolizumab

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.